Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy

Show full item record



Permalink

http://hdl.handle.net/10138/225316

Citation

Hemminki , O , Parviainen , S , Juhila , J , Turkki , R , Linder , N , Lundin , J , Kankainen , M , Ristimaki , A , Koski , A , Liikanen , I , Oksanen , M , Nettelbeck , D M , Kairemo , K , Partanen , K , Joensuu , T , Kanerva , A & Hemminki , A 2015 , ' Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy ' , Oncotarget , vol. 6 , no. 6 , pp. 4467-4481 . https://doi.org/10.18632/oncotarget.2901

Title: Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy
Author: Hemminki, Otto; Parviainen, Suvi; Juhila, Juuso; Turkki, Riku; Linder, Nina; Lundin, Johan; Kankainen, Matti; Ristimaki, Ari; Koski, Anniina; Liikanen, Ilkka; Oksanen, Minna; Nettelbeck, Dirk M.; Kairemo, Kalevi; Partanen, Kaarina; Joensuu, Timo; Kanerva, Anna; Hemminki, Akseli
Contributor: University of Helsinki, Transplantation Laboratory
University of Helsinki, Transplantation Laboratory
University of Helsinki, Transplantation Laboratory
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, CSC - IT Center for Science
University of Helsinki, Medicum
University of Helsinki, Transplantation Laboratory
University of Helsinki, Transplantation Laboratory
University of Helsinki, Medicum
University of Helsinki, Docrates Canc Ctr
University of Helsinki, Docrates Canc Ctr
University of Helsinki, Clinicum
University of Helsinki, Medicum
Date: 2015-02-28
Language: eng
Number of pages: 15
Belongs to series: Oncotarget
ISSN: 1949-2553
URI: http://hdl.handle.net/10138/225316
Abstract: Oncolytic viruses that selectively replicate in tumor cells can be used for treatment of cancer. Accumulating data suggests that virus induced oncolysis can enhance anti-tumor immunity and break immune tolerance. To capitalize on the immunogenic nature of oncolysis, we generated a quadruple modified oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor (GMCSF). Ad5/3-E2F-Delta 24-GMCSF (CGTG-602) was engineered to contain a tumor specific E2F1 promoter driving an E1 gene deleted at the retinoblastoma protein binding site ("Delta 24"). The fiber features a knob from serotype 3 for enhanced gene delivery to tumor cells. The virus was tested preclinically in vitro and in vivo and then 13 patients with solid tumors refractory to standard therapies were treated. Treatments were well tolerated and frequent tumor-and adenovirus-specific T-cell immune responses were seen. Overall, with regard to tumor marker or radiological responses, signs of antitumor efficacy were seen in 9/12 evaluable patients (75%). The radiological disease control rate with positron emission tomography was 83% while the response rate (including minor responses) was 50%. Tumor biopsies indicated accumulation of immunological cells, especially T-cells, to tumors after treatment. RNA expression analyses of tumors indicated immunological activation and metabolic changes secondary to virus replication.
Subject: Oncolytic
immunotherapy
cancer
ATAP
CHEMOTHERAPY-REFRACTORY CANCER
ANTITUMOR IMMUNE-RESPONSES
COLONY-STIMULATING FACTOR
ONCOLYTIC ADENOVIRUS
OVARIAN-CANCER
T-CELL
GM-CSF
THERAPEUTIC-EFFICACY
RETINOIC ACID
SOLID TUMORS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
2901_41148_3_PB.pdf 2.806Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record